Progression-free survival Kaplan-Meier estimates of the probability of... | Download Scientific Diagram
Impact of cabazitaxel on 2-year survival and palliation of tumour-related pain in men with metastatic castration-resistant prostate cancer treated in the TROPIC trial - Annals of Oncology
Patient Preference Between Cabazitaxel and Docetaxel for First-line Chemotherapy in Metastatic Castration-resistant Prostate Cancer: The CABADOC Trial - European Urology
Significance of De Ritis (Aspartate Transaminase/Alanine Transaminase) Ratio as a Significant Prognostic But Not Predictive Biomarker in Japanese Patients with Metastatic Castration-resistant Prostate Cancer Treated with Cabazitaxel | Anticancer Research
The efficacy and toxicity of cabazitaxel for treatment of docetaxel-resistant prostate cancer correlating with the initial doses in Japanese patients | BMC Cancer | Full Text
Cabazitaxel shows a consistently greater survival benefit compared to mitoxantrone in patients with mCRPC | de Bono | Nowotwory. Journal of Oncology
Jevtana: new option for metastatic prostate cancer | MIMS online
Cabazitaxel versus Abiraterone or Enzalutamide in Metastatic Prostate Cancer | NEJM
Kaplan-Meier estimates of the probability of overall survival (OS) and... | Download Scientific Diagram
1415-Prostate metastatic cabazitaxel three weekly and prednisolone | eviQ
Clinical Trial Results for JEVTANA® (cabazitaxel) Injection
Cabazitaxel versus Abiraterone or Enzalutamide in Metastatic Prostate Cancer | NEJM
Overall and progression-free survival with cabazitaxel in metastatic castration-resistant prostate cancer in routine clinical practice: the FUJI cohort | British Journal of Cancer
Prognostic Impact of Prior Androgen Receptor Axis-targeting Agents in Cabazitaxel Chemotherapy After Docetaxel | Anticancer Research
Therapeutic Outcome of >10 Cycles of Cabazitaxel for Castration-resistant Prostate Cancer: A Multi-institutional Study | Anticancer Research
Kaplan-Meier estimates of the probability of overall survival (OS) and... | Download Scientific Diagram
Overall survival (OS) after cabazitaxel treatment. a OS in the... | Download Scientific Diagram
Optimal Timing of Cabazitaxel Introduction for Japanese Patients With Metastatic Castration-resistant Prostate Cancer | Anticancer Research
Progression-free survival (PFS) after cabazitaxel treatment. a PFS in... | Download Scientific Diagram
Impact of cabazitaxel on 2-year survival and palliation of tumour-related pain in men with metastatic castration-resistant prostate cancer treated in the TROPIC trial - Annals of Oncology
Efficacy of cabazitaxel and the influence of clinical factors on the overall survival of patients with castration‐resistant prostate cancer: A local experience of a multicenter retrospective study - Takai - 2021 -
Overall and progression-free survival with cabazitaxel in metastatic castration-resistant prostate cancer in routine clinical practice: the FUJI cohort | British Journal of Cancer
Overall survival (OS) after cabazitaxel treatment. a OS in the... | Download Scientific Diagram
Treatment Decisions for Metastatic Castration-resistant Prostate Cancer Progressing After Docetaxel Chemotherapy: The Role of Cabazitaxel in the Continuum of Care - European Urology
